NeuroFlow helps risk-bearing healthcare organizations improve outcomes and cost of care in complex populations by surfacing and supporting behavioral health needs that typically go undetected and under-addressed. Across payors, providers, and the federal government, NeuroFlow’s scalable technology and analytics capabilities empower organizations with actionable intelligence from real-time data collection and risk stratification, enabling them to manage populations in a financially sustainable way. Powered by deep expertise in whole-person care, NeuroFlow offers a path to risk predictability and proactive care that helps overcome the systemic challenges in today’s healthcare ecosystem.
NeuroVista Corporation was an early-stage medical device company pioneering new technologies that will revolutionize the management and treatment of epilepsy, a neurological condition affecting approximately 1% of the U.S. population—more than Parkinson's disease, multiple sclerosis and Lou Gehrig's disease combined.